Literature DB >> 24076532

Left atrial volume index: relation to long-term clinical outcome in type 2 diabetes.

Mikael K Poulsen1, Jordi S Dahl2, Jan Erik Henriksen3, Thomas M Hey2, Poul Flemming Høilund-Carlsen4, Henning Beck-Nielsen3, Jacob E Møller2.   

Abstract

OBJECTIVES: The study sought to determine the prognostic importance of left atrial (LA) dilation in patients with type 2 diabetes mellitus (T2DM) and no history of cardiovascular disease (CVD).
BACKGROUND: T2DM is associated with the development of CVD, and morphological changes in the heart may appear before symptoms arise.
METHODS: A total of 305 T2DM patients without known CVD referred to a diabetes clinic were included consecutively (age 58.6 ± 11.3 years, diabetes duration 2.0 [interquartile range: 0 to 6.0] years). Each patient underwent a comprehensive echocardiogram and a myocardial perfusion scintigraphy (MPS) at inclusion. Patients were divided according to left atrial volume index (LAVi) ≥32 ml/m(2). Patients were followed for median of 5.6 (interquartile range: 5.1 to 6.1) years for the occurrence of major cardiac events and death.
RESULTS: LAVi ≥32 ml/m(2) was found in 105 patients (34%). During follow-up, 60 patients (20%) experienced the composite endpoint, of whom 28 (9%) died. Patients with LAVi ≥32 ml/m(2) had a significantly higher cardiac event rate and death rate (p < 0.001 and p = 0.002, respectively). Univariate predictors of the composite endpoint were age, hypertension, left ventricular diastolic function, E/e'septum-ratio and LAVi ≥32 ml/m(2); however, myocardial ischemia on MPS was not a predictor. When adjusting for age and hypertension, only LAVi ≥32 ml/m(2) was a predictor of the composite endpoint (hazard ratio: 1.82 [95% confidence interval: 1.08 to 3.07], p = 0.024).
CONCLUSIONS: Increased LAVi was an independent and incremental predictor of cardiovascular morbidity and mortality in T2DM patients with no history of CVD. (Presence of Macrovascular Disease in Type 2 Diabetes Mellitus; NCT00298844).
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CVD; LAVi; LV; MACE; MPS; SSS; T2DM; cardiovascular disease; clinical outcome; echocardiography; left atrial volume index; left ventricular; major cardiovascular event(s); myocardial perfusion scintigraphy; summed stress score; type 2 diabetes mellitus

Mesh:

Year:  2013        PMID: 24076532     DOI: 10.1016/j.jacc.2013.08.1622

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  25 in total

1.  Left atrial dysfunction in type 2 diabetes mellitus: insights from cardiac MRI.

Authors:  Bruno Graça; Maria João Ferreira; Paulo Donato; Leonor Gomes; Miguel Castelo-Branco; Filipe Caseiro-Alves
Journal:  Eur Radiol       Date:  2014-07-17       Impact factor: 5.315

2.  Is Left Atrial Size a Predictor of Mortality after Coronary Artery Bypass Surgery? A Single Center Study.

Authors:  Khalid S Ibrahim; Fadia A Mayyas; Khalid Kheirallah; Nizar R AlWaqfi; David R Van Wagoner
Journal:  Acta Cardiol Sin       Date:  2017-03       Impact factor: 2.672

3.  Comparing the influence of 2009 versus 2016 ASE/EACVI diastolic function guidelines on the prevalence and echocardiographic characteristics of preclinical diastolic dysfunction (stage B heart failure) in a Hispanic population with type 2 diabetes mellitus.

Authors:  Siu-Hin Wan; Andrew S Pumerantz; Fanglong Dong; Cesar Ochoa; Horng H Chen
Journal:  J Diabetes Complications       Date:  2019-05-07       Impact factor: 2.852

4.  Left atrial remodeling, hypertrophy, and fibrosis in mouse models of heart failure.

Authors:  Waqas Hanif; Linda Alex; Ya Su; Arti V Shinde; Ilaria Russo; Na Li; Nikolaos G Frangogiannis
Journal:  Cardiovasc Pathol       Date:  2017-06-21       Impact factor: 2.185

Review 5.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

6.  Left ventricular systolic dysfunction predicts long-term major microvascular complication outcomes in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications (EDC) study of childhood onset diabetes.

Authors:  Jingchuan Guo; Rachel G Miller; Tina Costacou; William P Follansbee; Trevor J Orchard
Journal:  J Diabetes Complications       Date:  2017-12-28       Impact factor: 2.852

Review 7.  Echocardiographic feature of diabetic cardiomyopathy: where are we now?

Authors:  Kazuaki Negishi
Journal:  Cardiovasc Diagn Ther       Date:  2018-02

8.  Redefining Cirrhotic Cardiomyopathy for the Modern Era.

Authors:  Manhal Izzy; Lisa B VanWagner; Grace Lin; Mario Altieri; James Y Findlay; Jae K Oh; Kymberly D Watt; Samuel S Lee
Journal:  Hepatology       Date:  2019-10-11       Impact factor: 17.425

9.  Left and right atrial phasic function and deformation in untreated patients with prediabetes and type 2 diabetes mellitus.

Authors:  Marijana Tadic; Sanja Ilic; Cesare Cuspidi; Branislava Ivanovic; Ljiljana Bukarica; Nada Kostic; Tamara Marjanovic; Vesna Kocijancic; Vera Celic
Journal:  Int J Cardiovasc Imaging       Date:  2014-09-12       Impact factor: 2.357

10.  Association of left atrial structure and function and incident cardiovascular disease in patients with diabetes mellitus: results from multi-ethnic study of atherosclerosis (MESA).

Authors:  Timothy M Markman; Mohammadali Habibi; Bharath Ambale Venkatesh; Mytra Zareian; Colin Wu; Susan R Heckbert; David A Bluemke; Joao A C Lima
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2017-10-01       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.